Log in

NASDAQ:BCYCBicycle Therapeutics Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$15.35
MA: $16.65
$19.25
52-Week Range N/A
Volume125 shs
Average Volume28,643 shs
Market Capitalization$279.42 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.56
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCYC
CUSIPN/A
CIKN/A
Phone44-12-2326-1503

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.80 million
Book Value$4.01 per share

Profitability

Net Income$-30,610,000.00
Net Margins-434.29%

Miscellaneous

Employees61
Market Cap$279.42 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Bicycle Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bicycle Therapeutics
.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Bicycle Therapeutics
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics Limited (NASDAQ:BCYC) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.67) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.19. Bicycle Therapeutics had a negative net margin of 434.29% and a negative return on equity of 43.74%.
View Bicycle Therapeutics' earnings history
.

What price target have analysts set for BCYC?

5 analysts have issued 1 year target prices for Bicycle Therapeutics' shares. Their forecasts range from $14.00 to $27.00. On average, they expect Bicycle Therapeutics' share price to reach $21.30 in the next year.
View analysts' price targets for Bicycle Therapeutics
.

Has Bicycle Therapeutics been receiving favorable news coverage?

News articles about BCYC stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bicycle Therapeutics earned a news sentiment score of -4.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Bicycle Therapeutics
.

Who are some of Bicycle Therapeutics' key competitors?

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Beyond Meat (BYND), AbbVie (ABBV), Cronos Group (CRON), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Intra-Cellular Therapies (ITCI), NovaBay Pharmaceuticals (NBY), Occidental Petroleum (OXY), Pfizer (PFE) and Ring Energy (REI).

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:
  • Dr. Kevin Lee M.B.A., Ph.D., CEO & Director (Age 51)
  • Mr. Lee H. Kalowski, Pres & CFO (Age 38)
  • Mr. Christian Heinis, Scientific Founder
  • Sir Gregory Winter, Co-Founder, Director & Member of Scientific Advisory Board (Age 68)
  • Mr. Michael Skynner, Chief Operating Officer (Age 50)

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.01%). Company insiders that own Bicycle Therapeutics stock include Deborah Harland and Life Sciences Fund V Lp Sv.
View institutional ownership trends for Bicycle Therapeutics
.

Which institutional investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Bicycle Therapeutics stock in the last two years include Deborah Harland, and Life Sciences Fund V Lp Sv.
View insider buying and selling activity for Bicycle Therapeutics
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Bicycle Therapeutics?

Bicycle Therapeutics has a market capitalization of $0.00 and generates $13.80 million in revenue each year. The company earns $-30,610,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. Bicycle Therapeutics employs 61 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 44-12-2326-1503.

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.